Abbott's FreeStyle® Libre 2 iCGM Cleared in U.S. for Adults and Children with Diabetes, Achieving Highest Level of Accuracy and Performance Standards - Jun 15, 2020
Abbott (NYSE: ABT), the worldwide leader in continuous glucose monitoring (CGM), announced today the U.S. Food and Drug Administration (FDA) cleared its next-generation FreeStyle® Libre 2
Freestyle Libre 2 CGM, Strategy and Strength
Healthy Living Now Providing the Abbott Freestyle Libre to Medicare Members — Healthy Living Medical Supply
FreeStyle Libre 2 System
FreeStyle Libre 2 System (CGM)
FreeStyle Libre 2 Continuous Glucose Monitor
2 Million Patients And Beyond: Abbott's FreeStyle Libre 2 Cleared In The U.S. For Adults And Children With Diabetes
2 Million Patients And Beyond: Abbott's FreeStyle Libre 2 Cleared In The U.S. For Adults And Children With Diabetes
Freestyle Libre 2 - Continuous Glucose Monitoring System
Intermittently scanned continuous glucose monitoring is associated with high satisfaction but increased HbA1c and weight in well‐controlled youth with type 1 diabetes - Charleer - 2020 - Pediatric Diabetes - Wiley Online Library
ADA: Real-world data show lower A1c levels with Abbott's FreeStyle Libre CGM in Type 2 diabetes
New Study Published in The New England Journal of Medicine Demonstrates Abbott's FreeStyle Libre® 2 System Has Positive Impacts on Glucose Levels and Quality of Life - Oct 6, 2022
Abbott's FreeStyle Libre 2 CGM picks up Medicare coverage
FreeStyle Libre 2 Continuous Glucose Monitor
FreeStyle Libre 2 Continuous Glucose Monitor
FreeStyle Libre 2 System
